Actinogen Medical Limited

ACW.ASX

Health Care

Development and commercialisation of new therapeutic compounds

Market Data

Price

$0.038

-0.0%
Market Cap

$146.3M

P/E Ratio

-100000.0x

EPS

$-0.006

Div. Yield

0.00%

52-Week Change

-0.2%

Latest Earnings

Actinogen HY2025 financial report and Appendix 4D

26 February 2026

Revenue
$0.23
-4.7% YoY
NPAT
-$11.35
-39.0% YoY
EPS
$-0.00

Actinogen Medical reported a HY2025 net loss of $11.3M, a 39% increase from $8.2M in the prior corresponding period, primarily driven by increased R&D spending of $8.9M. Key highlight was completing enrollment of 247 participants in the pivotal XanaMIA Alzheimer's trial and receiving a positive interim safety and efficacy recommendation from the Data Monitoring Committee. The company received $7.4M in R&D tax incentives and secured an additional $4.3M non-dilutive funding post-period. Key points: Completed enrollment of 247 participants in pivotal XanaMIA phase 2b/3 AD trial (exceeded target of 220); Received positive interim safety and efficacy futility analysis recommendation from independent Data Monitoring Committee; Achieved common understanding with FDA on pathway to marketing approval including streamlined design of one additional pivotal trial

Recent Announcements

26 Feb 2026 Actual Results Positive

Actinogen HY2025 financial report and Appendix 4D

Actinogen Medical reported a HY2025 net loss of $11.3M, a 39% increase from $8.2M in the prior corresponding period, primarily driven by increased R&D spending of $8.9M. Key highlight was completing enrollment of 247 participants in the pivotal XanaMIA Alzheimer's trial and receiving a positive interim safety and efficacy recommendation from the Data Monitoring Committee. The company received $7.4M in R&D tax incentives and secured an additional $4.3M non-dilutive funding post-period. Key points: Completed enrollment of 247 participants in pivotal XanaMIA phase 2b/3 AD trial (exceeded target of 220); Received positive interim safety and efficacy futility analysis recommendation from independent Data Monitoring Committee; Achieved common understanding with FDA on pathway to marketing approval including streamlined design of one additional pivotal trial

Get real-time alerts for ACW

Receive AI-powered earnings summaries and instant notifications when Actinogen Medical Limited releases results.

Register Free